Search - tctmd.com

Displaying 41 - 60 of 137

Sort: Relevancy | Date

More Support for Single Antiplatelet Therapy After TAVI

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

Optimal antithrombotic regimen after transcatheter aortic valve replacement (TAVR): long term follow-up study

Presentation TVT 2022

Optimal antithrombotic regimen after transcatheter aortic valve replacement (TAVR): long term follow-up study

Presenter: Melissa Moey

June 09, 2022

LAA Occlusion With Watchman Provides Good Early Results in China

News Daily News

LAA Occlusion With Watchman Provides Good Early Results in China

June 07, 2022

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

News Conference News EuroPCR 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

Yael L. Maxwell

May 23, 2022

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Presentation TCT 2021

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Presenter: Stephan Windecker

November 05, 2021

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.